Literature DB >> 22908150

Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6.

Toni L Lamoureaux1, Hilary Frase, Nuno T Antunes, Sergei B Vakulenko.   

Abstract

The class A carbapenemase KPC-6 produces resistance to a broad range of β-lactam antibiotics. This enzyme hydrolyzes penicillins, the monobactam aztreonam, and carbapenems with similar catalytic efficiencies, ranging from 10(5) to 10(6) M(-1) s(-1). The catalytic efficiencies of KPC-6 against cephems vary to a greater extent, ranging from 10(3) M(-1) s(-1) for the cephamycin cefoxitin and the extended-spectrum cephalosporin ceftazidime to 10(5) to 10(6) M(-1) s(-1) for the narrow-spectrum and some of the extended-spectrum cephalosporins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908150      PMCID: PMC3486543          DOI: 10.1128/AAC.01338-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.

Authors:  Jimena Alba; Yoshikazu Ishii; Kenneth Thomson; Ellen Smith Moland; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts.

Authors:  H C Neu; L A Heppel
Journal:  J Biol Chem       Date:  1965-09       Impact factor: 5.157

4.  Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Authors:  H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Class A carbapenemase FPH-1 from Francisella philomiragia.

Authors:  Marta Toth; Viktoria Vakulenko; Nuno T Antunes; Hilary Frase; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

6.  Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.

Authors:  Delphine Girlich; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

Review 7.  Class A carbapenemases.

Authors:  Jan Walther-Rasmussen; Niels Høiby
Journal:  J Antimicrob Chemother       Date:  2007-06-26       Impact factor: 5.790

8.  Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases.

Authors:  Hilary Frase; Qicun Shi; Sebastian A Testero; Shahriar Mobashery; Sergei B Vakulenko
Journal:  J Biol Chem       Date:  2009-08-05       Impact factor: 5.157

Review 9.  The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

Authors:  Patrice Nordmann; Gaelle Cuzon; Thierry Naas
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

10.  Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.

Authors:  Daniel J Wolter; Philip M Kurpiel; Neil Woodford; Marie-France I Palepou; Richard V Goering; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

View more
  8 in total

1.  Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae.

Authors:  Asma Khatri; Nina Naeger Murphy; Peter Wiest; Melissa Osborn; Kathleen Garber; Michelle Hecker; Kelly Hurless; Susan D Rudin; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; David van Duin; Federico Perez; Robert A Bonomo; David L Paterson; Patrick N A Harris
Journal:  Antimicrob Agents Chemother       Date:  2015-08       Impact factor: 5.191

2.  TEM,CTX-M,SHV Genes in ESBL-Producing Escherichia coli and Klebsiella pneumoniae Isolated from Clinical Samples in a County Clinical Emergency Hospital Romania-Predominance of CTX-M-15.

Authors:  Alice Elena Ghenea; Ovidiu Mircea Zlatian; Oana Mariana Cristea; Anca Ungureanu; Radu Razvan Mititelu; Andrei Theodor Balasoiu; Corina Maria Vasile; Alex-Ioan Salan; Daniel Iliuta; Mihaela Popescu; Anca-Loredana Udriștoiu; Maria Balasoiu
Journal:  Antibiotics (Basel)       Date:  2022-04-10

3.  A novel extended-spectrum β-lactamase, SGM-1, from an environmental isolate of Sphingobium sp.

Authors:  Toni L Lamoureaux; Viktoria Vakulenko; Marta Toth; Hilary Frase; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

4.  C6 Hydroxymethyl-Substituted Carbapenem MA-1-206 Inhibits the Major Acinetobacter baumannii Carbapenemase OXA-23 by Impeding Deacylation.

Authors:  Nichole K Stewart; Marta Toth; Maha A Alqurafi; Weirui Chai; Thu Q Nguyen; Pojun Quan; Mijoon Lee; John D Buynak; Clyde A Smith; Sergei B Vakulenko
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

5.  Natural Variants of the KPC-2 Carbapenemase have Evolved Increased Catalytic Efficiency for Ceftazidime Hydrolysis at the Cost of Enzyme Stability.

Authors:  Shrenik C Mehta; Kacie Rice; Timothy Palzkill
Journal:  PLoS Pathog       Date:  2015-06-01       Impact factor: 6.823

Review 6.  Carbapenemase-producing Klebsiella pneumoniae.

Authors:  Elizabeth Robilotti; Stan Deresinski
Journal:  F1000Prime Rep       Date:  2014-09-04

Review 7.  A structural, epidemiological & genetic overview of Klebsiella pneumoniae carbapenemases (KPCs).

Authors:  C H Swathi; Rosy Chikala; K S Ratnakar; V Sritharan
Journal:  Indian J Med Res       Date:  2016-07       Impact factor: 2.375

8.  KPC-2 β-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate.

Authors:  Shrenik C Mehta; Ian M Furey; Orville A Pemberton; David M Boragine; Yu Chen; Timothy Palzkill
Journal:  J Biol Chem       Date:  2020-12-10       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.